Search results
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
Digital Journal· 58 minutes agoGSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and ...